Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT01201616 Completed - Clinical trials for Mild Cognitive Impairment

The Effects of Diet on Mood, Cognition and Appetite

Start date: July 2010
Phase: N/A
Study type: Interventional

A previous study has found that the consumption of a high fat, low carbohydrate meal results in increased feelings of calmness, friendliness and an increase in subjective energy levels in comparison to a low fat, high carbohydrate meal. The purpose of this study is to investigate whether a high fat, low carbohydrate diet for a longer duration (of 2 weeks) can enhance or sustain these changes in comparison to a low fat, high carbohydrate meal.

NCT ID: NCT01151670 Completed - Clinical trials for Glioblastoma Multiforme

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Start date: August 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Pioglitazone hydrochloride may be effective treatment for cognitive dysfunction caused by radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of pioglitazone hydrochloride in preventing radiation-induced cognitive dysfunction in treating patients with brain tumors.

NCT ID: NCT01146717 Completed - Clinical trials for Mild Cognitive Impairment

Aerobic Exercise Training in Mild Cognitive Impairment Study

AETMCI
Start date: March 2010
Phase: N/A
Study type: Interventional

This study is being done to find out whether regulation of brain blood flow is altered in patents with mild cognitive impairment (those who have memory problems but otherwise healthy) when compared with healthy elderly individuals. In addition, this study will determine whether exercise training improves brain blood flow, brain structure, and brain function in patients with mild cognitive impairment (MCI). This is a research study because at present the investigators know little about brain blood flow regulation in patients with mild cognitive impairment. The investigators also know little about whether exercise training improves brain blood flow, brain structure, and brain function in patients with mild cognitive impairment.

NCT ID: NCT01121497 Not yet recruiting - Clinical trials for Cognitive Dysfunction

The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy

Start date: July 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the administration of physostigmine in combination with sedation for colonoscopy can minimize the cognitive decline at the time of hospital discharge

NCT ID: NCT01113242 Completed - Clinical trials for Parkinson Disease Dementia

Neuropsychological Assessment of Cognitive Decline in Patients With a Definite Parkinson's Disease

Start date: June 2010
Phase:
Study type: Observational

Cognitive disorders in Parkinson's disease (PD) are not as obvious as cognitive disorders in Alzheimer disease and their diagnosis tends to be delayed. If neuropsychological assessment of cognitive decline in Parkinson's disease is well established, the thresholds of cognitive testing corresponding to a dementia are unknown. Recently, new diagnosis criteria of dementia associated with PD have been proposed by the movement disorder society. In this study two groups of patients with idiopathic PD will be separated and compared according to their Mini Mental State Examination (MMSE) score (upper or lower than 26). Included patients will have clinically idiopathic PD, will be over 65 years old and will present cognitive complain. Cognitive and mood disorders as well as motor symptoms will be assessed using validated scales and a neuropsychological assessment dispatched in two visits will be performed . Differences in the distribution of data from the two groups of patients will be assessed in statistically analysis with non parametric tests. The purpose of this study is to determine the most effective tests and their threshold value corresponding to a pathological cognitive decline.

NCT ID: NCT01103453 Unknown status - Clinical trials for Mild Cognitive Impairment

Change in Executive Function and IADL Using a Virtual Supermarket Environment Among People With MCI

EF-VAPS
Start date: November 2010
Phase: Phase 1
Study type: Interventional

The aim of the study is to investigate the feasibility of using a virtual supermarket as an intervention tool for overcoming deficits in executive function as well as enhancing IADL performance among persons with Mild Cognitive Impairment. The working hypotheses are that there will be improvement in executive functions, and the improvement in the executive functions will result in better performance in Instrumental Activities of Daily Living, both generally and especially in shopping task

NCT ID: NCT01095562 Completed - Clinical trials for Cognitive Deficits in Schizophrenia

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Start date: March 2010
Phase: Phase 2
Study type: Interventional

This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.

NCT ID: NCT01087775 Completed - Clinical trials for Cognitive Impairment

GAME Veterans With PTSD Using Computer-Based Cognitive Training

Start date: April 2010
Phase: N/A
Study type: Interventional

The investigators hypothesis are as follows: H1a: OEF/OIF veterans with PTSD who perform cognitive training (CT) will demonstrate greater objective improvements on standard (untrained) neurocognitive measures, with the largest gains in verbal memory, learning and sustained attention. H1b: Objective cognitive improvements in CT participants will be sustained at three months post-intervention, suggesting persistence of neuroplasticity-based cognitive training benefits. H2a: OEF/OIF veterans with PTSD who perform CT will report greater improvements in cognitive function. H2b: OEF/OIF veterans with PTSD who perform CT will demonstrate improved social and occupational functioning and quality of life. H2c: OEF/OIF veterans with PTSD who perform CT will demonstrate greater improvements in community reintegration.

NCT ID: NCT01077700 Completed - Clinical trials for Cognitive Deficits in Schizophrenia

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Start date: March 2010
Phase: Phase 2
Study type: Interventional

This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.

NCT ID: NCT01055392 Unknown status - Alzheimer Disease Clinical Trials

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Start date: March 2007
Phase: Phase 2
Study type: Interventional

Lithium salts have been used for the treatment of psychiatric disorders for over five decades, mostly as a mood-stabilizing drug. Recent evidence points to the inhibition of the enzyme glycogen synthase kinase-3beta (GSK3) as one of its mechanisms of action. The overactivity of this enzyme has been implicated in the pathogenesis of Alzheimer's disease (AD), given its involvement in mechanisms related to the hyperphosphorylation of Tau protein and the production of beta-amyloid peptide. These are key events leading respectively to the formation of neurofibrillary tangles and senile plaques, which are the neuropathological hallmarks of the disease. Several in vitro and animal studies have shown that the inhibition of GSK3 by lithium and other agents attenuates these pathological processes, reinforcing the notion that GSK3 is a likely target for future disease-modifying therapies for AD. Indeed, a recent study published by our group showed that chronic lithium use is associated with a decrement in the expected prevalence of dementia, in a sample of elderly individuals with bipolar disorder. To investigate this putative neuroprotective effect in a prospective way, the investigators started 24-month randomized, double-blinded controlled trial of lithium for the prevention of dementia in a sample of elderly individuals with amnestic mild cognitive impairment (MCI), a condition associated with increased risk for the development of AD. The clinical and biological outcomes of this trial include the attenuation of cognitive deficits, and the modification of certain biological markers of the disease (as measured in the cerebrospinal fluid, leukocytes and platelets). The objective of the present application is to enable the extension of this ongoing trial to an additional 2-year follow-up. A longer follow-up (48 months) will increase the statistical power to ascertain the primary outcome variables of this study, particularly the con-version from MCI to Alzheimer's disease. This will warrant a more consistent conclusion about the potential of lithium treatment in the prevention of dementia, in addition to a better evaluation of safety and tolerability profiles of the long-term use of lithium in older individuals.